Unlike Pfizer and Moderna’s messenger RNA vaccines, Novavax uses tiny particles studded with viral proteins, mixed with an immune-boosting compound called adjuvant. The vaccine is given as two doses three weeks apart.
Novavax’s COVID-19 vaccine candidate is 90.4 percent effective at preventing infection, according to a study published Dec. 15. The study also found the vaccine was 100 percent effective at preventing moderate and severe disease. The drugmaker has said its vaccine can protect against the omicron variant, though it’s unclear how strong the protection will be, according to The New York Times.
In 2020, the U.S. government ordered 110 million doses of the shot from Novavax.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
